Short Interest in LAVA Therapeutics (NASDAQ:LVTX) Decreases By 50.6%

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 191,500 shares, a decrease of 50.6% from the February 28th total of 387,300 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average trading volume of 417,100 shares, the days-to-cover ratio is presently 0.5 days.

LAVA Therapeutics Price Performance

LVTX stock traded down $0.01 during mid-day trading on Friday, reaching $1.29. 43,333 shares of the company’s stock were exchanged, compared to its average volume of 173,459. The company has a market cap of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. LAVA Therapeutics has a 12-month low of $0.85 and a 12-month high of $3.57. The stock’s 50 day moving average is $1.13 and its 200 day moving average is $1.37.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.18. The company had revenue of $2.50 million during the quarter, compared to analyst estimates of $2.40 million. On average, research analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LVTX. Sanofi acquired a new position in shares of LAVA Therapeutics during the fourth quarter valued at approximately $1,825,000. BNP Paribas Financial Markets purchased a new stake in shares of LAVA Therapeutics during the fourth quarter worth approximately $40,000. Finally, Virtu Financial LLC acquired a new position in LAVA Therapeutics in the 3rd quarter valued at $32,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. HC Wainwright restated a “neutral” rating and issued a $1.50 target price (down previously from $2.00) on shares of LAVA Therapeutics in a research note on Thursday, February 27th. JMP Securities restated a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.17.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.